673,276 Shares in Thermo Fisher Scientific Inc. $TMO Purchased by Jupiter Topco LLC

Jupiter Topco LLC acquired a new position in Thermo Fisher Scientific Inc. (NYSE:TMO) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 673,276 shares of the medical research company’s stock, valued at approximately $337,521,000. Jupiter Topco LLC owned 0.18% of Thermo Fisher Scientific at the end of the most recent reporting period.

Other hedge funds have also recently modified their holdings of the company. J. Stern & Co. LLP boosted its holdings in Thermo Fisher Scientific by 58,006.4% during the 4th quarter. J. Stern & Co. LLP now owns 31,509,332 shares of the medical research company’s stock valued at $18,258,082,000 after acquiring an additional 31,455,105 shares during the period. BlackRock Inc. purchased a new stake in shares of Thermo Fisher Scientific during the second quarter valued at $15,501,867,000. Norges Bank purchased a new position in Thermo Fisher Scientific in the 4th quarter worth about $3,072,744,000. Bank of New York Mellon Corp bought a new position in Thermo Fisher Scientific in the 2nd quarter worth about $1,974,561,000. Finally, Auto Owners Insurance Co raised its stake in shares of Thermo Fisher Scientific by 57,845.0% during the fourth quarter. Auto Owners Insurance Co now owns 2,427,896 shares of the medical research company’s stock valued at $1,406,844,000 after acquiring an additional 2,423,706 shares in the last quarter. Institutional investors own 89.23% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on TMO shares. Stifel Nicolaus set a $650.00 target price on Thermo Fisher Scientific in a report on Wednesday, August 5th. Weiss Ratings upgraded Thermo Fisher Scientific from a “hold (c-)” rating to a “hold (c)” rating in a report on Tuesday, July 14th. Wells Fargo & Company cut their target price on shares of Thermo Fisher Scientific from $675.00 to $615.00 and set an “overweight” rating on the stock in a research report on Friday, May 8th. Morgan Stanley upped their price target on shares of Thermo Fisher Scientific from $620.00 to $650.00 and gave the stock an “overweight” rating in a research report on Friday, July 24th. Finally, Sanford C. Bernstein started coverage on shares of Thermo Fisher Scientific in a report on Friday, June 26th. They set a “market perform” rating and a $520.00 price objective on the stock. One research analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and six have given a Hold rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $619.41.

Thermo Fisher Scientific Price Performance

NYSE TMO opened at $627.96 on Wednesday. Thermo Fisher Scientific Inc. has a 12-month low of $435.27 and a 12-month high of $647.00. The firm’s fifty day simple moving average is $548.75 and its two-hundred day simple moving average is $510.05. The company has a current ratio of 1.55, a quick ratio of 1.18 and a debt-to-equity ratio of 0.74. The firm has a market capitalization of $232.19 billion, a P/E ratio of 33.78, a P/E/G ratio of 2.56 and a beta of 0.85.

Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share for the quarter, topping the consensus estimate of $5.71 by $0.32. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%.The firm had revenue of $11.99 billion for the quarter, compared to the consensus estimate of $11.71 billion. During the same period in the previous year, the business earned $4.28 EPS. The firm’s revenue for the quarter was up 10.5% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. Analysts forecast that Thermo Fisher Scientific Inc. will post 25.12 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, October 15th. Investors of record on Tuesday, September 15th will be paid a $0.47 dividend. The ex-dividend date is Tuesday, September 15th. This represents a $1.88 dividend on an annualized basis and a yield of 0.3%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 10.11%.

Insider Buying and Selling at Thermo Fisher Scientific

In other news, COO Gianluca Pettiti sold 400 shares of the firm’s stock in a transaction dated Monday, July 27th. The stock was sold at an average price of $565.00, for a total value of $226,000.00. Following the completion of the transaction, the chief operating officer directly owned 24,651 shares in the company, valued at $13,927,815. This trade represents a 1.60% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction that occurred on Thursday, August 20th. The stock was sold at an average price of $629.27, for a total transaction of $6,292,700.00. Following the completion of the transaction, the chief executive officer owned 123,925 shares in the company, valued at approximately $77,982,284.75. This trade represents a 7.47% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 73,493 shares of company stock valued at $43,950,381. Company insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.